معرفی
Professor Helen McCarthy holds the Chair of Nanomedicine at Queen’s University Belfast’s School of Pharmacy and serves as Associate Pro-Vice-Chancellor for Academic Business Development. She previously held a 0.2FTE Professorship at Dublin City University’s School of Chemical Sciences (2020–2023). Her research focuses on non-viral delivery systems for nucleic acids and anionic molecules, with expertise in mRNA vaccines, nanoparticle synthesis, and gene-loaded biomaterials for bone repair and wound healing. She has supervised over 40 PhD students, secured £10M in non-dilutive funding, and spun out pHion Therapeutics (2017–2023), winning INVENT NI and the Vice-Chancellor’s Innovation Award. She chairs global partnership committees for Queen’s and advises Prostate Cancer UK.
- Education: Not explicitly detailed in text.
Research Interests: Her work spans mRNA vaccine development, nanomedicines for cancer, and advanced materials for medical applications. Current projects include mRNA therapies for AMD, hybrid delivery systems for targeted drug delivery, and collaborations with institutions like Trinity College Dublin and the University of Birmingham.
Article Trends: Recent publications emphasize nanoparticle-based drug delivery systems, mRNA vaccine design, and biomaterials for orthopaedic and wound healing applications. Key themes include sustained drug release, corrosion-resistant alloys, and HIV/contraception combination therapies.
- Awards: INVENT NI (2017), All-Ireland Seedcorn Awards (2017), Vice-Chancellor’s Innovation Award (2018).
Advising & Grants: Supervised >40 PhD students; secured £10M Innovate UK funding. Collaborations involve global pharmaceutical companies and organizations like the Cell and Gene Therapy Catapult.
Labs/Teams: Leads a research group with expertise in mRNA manufacturing, pre-clinical screening, and interdisciplinary partnerships in biologics development.
